AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in null cell tumors (n = 24)
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in gonadotrope tumors (n = 21)
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in tumors containing only GH (n = 6)
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of ERalpha mRNA splice variants in normal pituitaries (n = 6)
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of ERalpha variants in ER-positive prolactinomas
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of ERalpha exon 7 deletion variant in gonadotropin tumors
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ERbeta mRNA splice variant in ERbeta-positive tumors
Number of subjects: 77
Study 9814476 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblotting analysis of ERalpha and ERbeta proteins
Number of subjects: 77
Study 7858770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-sestamibi SPECT
Number of subjects: 38
Study 7858770 — intervention group
Group type: COMPARATOR
Intervention: Tl-201 SPECT
Number of subjects: 38
Study 7858770 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m-sestamibi and Tl-201
Number of subjects: 38
Study 2802123 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.15 mg/kg
Number of subjects: 21
Study 2802123 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4.53 mg/kg
Number of subjects: 21
Study 345570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy for anaemic adult villagers
Number of subjects: 0
Study 345570 — intervention group
Group type: COMPARATOR
Intervention: Oral iron and/or TCE for children aged 5-14 years
Number of subjects: 0
Study 31300842 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 182
Study 31300842 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 182
Study 27729167 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 218
Study 27729167 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 218
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (100 mg)
Number of subjects: 85
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (200 mg)
Number of subjects: 85
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (300 mg)
Number of subjects: 85
Study 26222559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (monotherapy)
Number of subjects: 85
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (200 mg, add-on to fibrates)
Number of subjects: 85
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (300 mg, add-on to fibrates)
Number of subjects: 85
Study 26222559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (add-on to fibrates)
Number of subjects: 85
Study 26222559 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 304801 (all doses)
Number of subjects: 85
Study 23821878 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous technique (two injections at the same time)
Number of subjects: 72
Study 23821878 — intervention group
Group type: COMPARATOR
Intervention: Sequential technique (one injection after the other)
Number of subjects: 72
Study 21875546 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) twice daily
Number of subjects: 250
Study 21875546 — intervention group
Group type: COMPARATOR
Intervention: BUD pMDI 160 μg × 2 inhalations (320 μg) twice daily
Number of subjects: 250
Study 18001802 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 80 mg per day
Number of subjects: 1392
Study 18001802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study 16826107 — intervention group
Group type: COMPARATOR
Intervention: Cemented fixation
Number of subjects: 85
Study 16826107 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented (HA coated) with screws
Number of subjects: 85
Study 16826107 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented (HA coated) without screws
Number of subjects: 85
Study 12566865 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 0
Study 12566865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11097536 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg x kg(‐1))
Number of subjects: 128
Study 11097536 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4, or 1 mg x kg(‐1))
Number of subjects: 128
Study 11097536 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 128
Study 9347278 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hot can configuration (common anode with proximal coil)
Number of subjects: 30
Study 9347278 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hot can configuration
Number of subjects: 30
Study 8443481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 21
Study 8443481 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 21
Study 8443481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21
Study 8443481 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 21
Study 3718908 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical haloperidol
Number of subjects: 20
Study 29792287 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 (600 mg oral once daily for 12 weeks)
Number of subjects: 23
Study 29792287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29792287 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690
Number of subjects: 23
Study 26878554 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1000 pulses; 1 Hz; 90% of the tibialis anterior motor threshold)
Number of subjects: 20
Study 26878554 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study 26878554 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20
Study 24519563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg intravenous, administered 90 seconds after (99m)Tc‐tetrofosmin injection)
Number of subjects: 158
Study 24519563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 22939709 — intervention group
Group type: EXPERIMENTAL
Intervention: Free bednet distribution
Number of subjects: 516
Study 22939709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidised bednet through agricultural loan programmes
Number of subjects: 516
Study 20923473 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol for 4 months
Number of subjects: 0
Study 20923473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol for 4 months
Number of subjects: 0
Study 18927301 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry test using five monoclonal antibodies
Number of subjects: 0
Study 18927301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 16805930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 70
Study 16805930 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 70
Study 14669885 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (infants who practiced the target actions before the retention interval)
Number of subjects: 0
Study 14669885 — intervention group
Group type: COMPARATOR
Intervention: No practice (infants who did not practice the target actions before the retention interval)
Number of subjects: 0
Study 14669885 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (infants who practiced)
Number of subjects: 0
Study 14669885 — intervention group
Group type: COMPARATOR
Intervention: No practice (infants who did not practice)
Number of subjects: 0
Study 10815320 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (FEC-G) in addition to amikacin-ceftriaxone and other antibiotics
Number of subjects: 0
Study 10815320 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy without granulocyte colony-stimulating factor
Number of subjects: 0
Study 8997670 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection
Number of subjects: 10
Study 8997670 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 10
Study 1472833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg per day
Number of subjects: 19
Study 1472833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg per day
Number of subjects: 19
Study 1472833 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg per day + Gemfibrozil 450 mg per day
Number of subjects: 19
Study 6424087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitrogen intake (290 to 579 mg/kg/d)
Number of subjects: 0
Study 6424087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake (280 mg/kg/d)
Number of subjects: 0
Study 6424087 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended intravenous amino acid intakes (2.3 to 2.7 g/kg/d)
Number of subjects: 0
Study 30514351 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Symptom Assessment‐Cancer (ESRA‐C) intervention group
Number of subjects: 0
Study 30514351 — intervention group
Group type: COMPARATOR
Intervention: Control group (electronic assessment alone)
Number of subjects: 0
Study 26850265 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month aerobic-resistance exercise intervention (3 times/week)
Number of subjects: 154
Study 26850265 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical activity group
Number of subjects: 154
Study 26850265 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects on Tamoxifen or no endocrine therapy
Number of subjects: 154
Study 26850265 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects on aromatase inhibitors (AIs)
Number of subjects: 154
Study 26850265 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with serum Vitamin D levels 20-29 ng/mL
Number of subjects: 154
Study 25155251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression Free Survival Rate at 9 weeks (PFSR-9)
Number of subjects: 605
Study 25155251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression Free Survival Rate at 18 weeks (PFSR-18)
Number of subjects: 605
Study 25155251 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation study results for PFSR-9
Number of subjects: 605
Study 25155251 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation study results for PFSR-18
Number of subjects: 605
Study 25155251 — intervention group
Group type: COMPARATOR
Intervention: Best overall response in validation study
Number of subjects: 605
Study 22863540 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 46
Study 22863540 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 46
Study 20441721 — intervention group
Group type: EXPERIMENTAL
Intervention: In virtuo plus in vivo exposure
Number of subjects: 31
Study 20441721 — intervention group
Group type: COMPARATOR
Intervention: In vivo exposure alone
Number of subjects: 31
Study 20441721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 31
Study 20441721 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 31
Study 18827210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-IM (intramuscular administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Number of subjects: 1005
Study 18827210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-IM (reduced 3-dose schedule of AVA; n = 501)
Number of subjects: 1005
Study 18827210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-SQ (subcutaneous administration of AVA at 0, 2, and 4 weeks and 6 months; n = 165-170)
Number of subjects: 1005
Study 18827210 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injections at the same time intervals; n = 169)
Number of subjects: 1005
Study 18827210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-IM vs 4-SQ
Number of subjects: 1005
Study 18827210 — intervention group
Group type: EXPERIMENTAL
Intervention: Route of administration
Number of subjects: 1005
Study 16313321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 124
Study 16313321 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 124
Study 16313321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold ischemia time >14.5 h
Number of subjects: 124
Study 16313321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient age
Number of subjects: 124
Study 16313321 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4 HLA-AB mismatches
Number of subjects: 124
Study 16313321 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 124
Study 11981349 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 380
Study 11981349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 10464886 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 micrograms once daily in the evening
Number of subjects: 181
Study 10464886 — intervention group
Group type: COMPARATOR
Intervention: Budesonide Turbuhaler 200 micrograms twice daily
Number of subjects: 181
Study 10464886 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 200 micrograms once daily during the first open treatment period
Number of subjects: 181
Study 10464886 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 100 micrograms once daily during the second open treatment period
Number of subjects: 181
Study 7818003 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 61
Study 7818003 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (open surgery)
Number of subjects: 61
Study 2169371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (60 mg daily)
Number of subjects: 40
Study 397800 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 21
Study 397800 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base
Number of subjects: 21
Study 31142364 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive skin care and prevention strategy
Number of subjects: 20
Study 31142364 — intervention group
Group type: COMPARATOR
Intervention: Standard skin care
Number of subjects: 20
Study 27770279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Temozolomide (TMZ) 75-100 mg/m2 day 1-21 of 28 day cycle
Number of subjects: 117
Study 27770279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Irinotecan (CPT) 125 mg/m2 every 2 weeks
Number of subjects: 117
Study 25785807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 471
Study 24035872 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage protocol (three sessions of 20 to 30 minutes on alternate days over a one-week period)
Number of subjects: 52
Study 24035872 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage session
Number of subjects: 52
Study 21982956 — intervention group
Group type: EXPERIMENTAL
Intervention: APDDR-0901 (0.03% retinol, 0.7% rose extract, 0.05% hexamidine diisethionate)
Number of subjects: 97
Study 21982956 — intervention group
Group type: COMPARATOR
Intervention: 0.1% adapalene gel
Number of subjects: 97
Study 21982956 — intervention group
Group type: EXPERIMENTAL
Intervention: APDDR-0901
Number of subjects: 97
Study 19132882 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute exercise duration group
Number of subjects: 33
Study 19132882 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-minute exercise duration group
Number of subjects: 33
Study 19132882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 16899841 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 2519
Study 16899841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusitis
Number of subjects: 2519
Study 15564937 — intervention group
Group type: EXPERIMENTAL
Intervention: Down shoulder position
Number of subjects: 30
Study 15564937 — intervention group
Group type: COMPARATOR
Intervention: Up shoulder position
Number of subjects: 30
Study 11445771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume familiarized eccentric exercise (LV+ECC)
Number of subjects: 0
Study 11445771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC)
Number of subjects: 0
Study 11445771 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 9670867 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone and exercise intervention
Number of subjects: 155
Study 9670867 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I levels treated as a continuous measure
Number of subjects: 155
Study 7529680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine
Number of subjects: 19
Study 7529680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3126956 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 302
Study 3126956 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 302
Study 3126956 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study 3126956 — intervention group
Group type: EXPERIMENTAL
Intervention: beta blockers (prior treatment)
Number of subjects: 302
Study 31256036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral insulin (7.5 mg for 2 months, 22.5 mg for 2 months, 67.5 mg until age 36.0 months)
Number of subjects: 0
Study 31256036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral insulin
Number of subjects: 0
Study 31256036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28291622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ezetimibe 10mg/d and rosuvastatin 10mg/d)
Number of subjects: 125
Study 28291622 — intervention group
Group type: COMPARATOR
Intervention: High-dose rosuvastatin (rosuvastatin 20mg/d)
Number of subjects: 125
Study 28291622 — intervention group
Group type: COMPARATOR
Intervention: Intermediate intensity rosuvastatin (rosuvastatin 10mg/d)
Number of subjects: 125
Study 25735400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814
Study 25735400 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 814
Study 23267856 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK249320 (0.04, 0.4, 1.2, 3.5, 10, and 25 mg/kg)
Number of subjects: 47
Study 23267856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22263329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (SnF2)
Number of subjects: 80
Study 22263329 — intervention group
Group type: COMPARATOR
Intervention: 8.0% arginine-calcium carbonate-sodium monofluorophosphate dentifrice (positive control)
Number of subjects: 80
Study 19930866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/day)
Number of subjects: 53
Study 19930866 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (up to 100 mg/day)
Number of subjects: 53
Study 16825591 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP56
Number of subjects: 518
Study 16825591 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP42
Number of subjects: 518
Study 16825591 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP45
Number of subjects: 518
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood loss in the hematoma group (762 ± 735 mL; median 500 mL)
Number of subjects: 49
Study 15021285 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative blood loss in the control group (415 ± 403 mL; median 300 mL)
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated intracranial pressure in the hematoma group (9/10 patients, 90%)
Number of subjects: 49
Study 15021285 — intervention group
Group type: COMPARATOR
Intervention: Elevated intracranial pressure in the control group (1/8 patients, 12.5%)
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 24 hours
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 6 hours
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical deterioration within 1 hour
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased level of consciousness
Number of subjects: 49
Study 15021285 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased focal neurologic signs
Number of subjects: 49
Study 11227030 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g n-3 PUFA as fish oil
Number of subjects: 62
Study 11227030 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g n-3 PUFA as fish oil
Number of subjects: 62
Study 11227030 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g n-3 PUFA as fish oil
Number of subjects: 62
Study 11227030 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 62
Study 10023558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free hernioplasty (Lichtenstein, TAPP)
Number of subjects: 280
Study 10023558 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 280
Study 7869368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 79
Study 7869368 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 79
Study 3148139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 20